State of New Jersey Common Pension Fund D - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 165 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2017. The put-call ratio across all filers is 1.57 and the average weighting 0.1%.

Quarter-by-quarter ownership
State of New Jersey Common Pension Fund D ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$2,436,214
+5.0%
68,337
+35.9%
0.01%
+12.5%
Q2 2023$2,319,970
+15.0%
50,2920.0%0.01%
+14.3%
Q1 2023$2,016,709
-35.4%
50,292
-25.3%
0.01%
-41.7%
Q4 2022$3,119,909
+59.3%
67,341
+42.4%
0.01%
+50.0%
Q3 2022$1,958,000
-30.6%
47,2890.0%0.01%
-27.3%
Q2 2022$2,821,000
-12.4%
47,289
+6.7%
0.01%
+10.0%
Q1 2022$3,220,000
-9.4%
44,338
+4.9%
0.01%0.0%
Q4 2021$3,556,000
-6.4%
42,284
+0.4%
0.01%
-16.7%
Q3 2021$3,800,000
+0.7%
42,132
+6.5%
0.01%0.0%
Q2 2021$3,773,000
-13.6%
39,570
+3.2%
0.01%
-20.0%
Q1 2021$4,368,000
-17.1%
38,360
+0.8%
0.02%
-21.1%
Q4 2020$5,268,000
+57.9%
38,055
-6.3%
0.02%
+46.2%
Q3 2020$3,337,000
+3.8%
40,604
-1.2%
0.01%0.0%
Q2 2020$3,215,000
+22.8%
41,096
-30.3%
0.01%0.0%
Q1 2020$2,619,000
+4.1%
58,9440.0%0.01%
+44.4%
Q4 2019$2,517,000
+28.5%
58,944
+28.7%
0.01%
+12.5%
Q3 2019$1,959,000
+228.1%
45,800
+387.2%
0.01%
+300.0%
Q2 2019$597,000
-8.4%
9,4000.0%0.00%0.0%
Q1 2019$652,000
+59.4%
9,4000.0%0.00%0.0%
Q4 2018$409,000
-43.0%
9,4000.0%0.00%
-33.3%
Q3 2018$718,000
-0.7%
9,4000.0%0.00%0.0%
Q2 2018$723,000
+50.9%
9,4000.0%0.00%
+50.0%
Q1 2018$479,000
+9.9%
9,4000.0%0.00%0.0%
Q4 2017$436,000
-13.0%
9,4000.0%0.00%0.0%
Q3 2017$501,000
-14.2%
9,4000.0%0.00%0.0%
Q2 2017$584,000
-8.3%
9,4000.0%0.00%
-33.3%
Q1 2017$637,000
-3.6%
9,4000.0%0.00%0.0%
Q4 2016$661,000
-0.9%
9,4000.0%0.00%0.0%
Q3 2016$667,000
+45.0%
9,4000.0%0.00%
+50.0%
Q2 2016$460,000
-22.7%
9,4000.0%0.00%
-33.3%
Q1 2016$595,000
-71.8%
9,400
-50.0%
0.00%
-25.0%
Q4 2015$2,108,000
+132.9%
18,800
+100.0%
0.00%0.0%
Q3 2015$905,000
-5.9%
9,4000.0%0.00%0.0%
Q2 2015$962,000
+64.7%
9,4000.0%0.00%
+100.0%
Q1 2015$584,000
+41.7%
9,4000.0%0.00%0.0%
Q4 2014$412,000
-22.6%
9,4000.0%0.00%0.0%
Q3 2014$532,000
+26.1%
9,4000.0%0.00%0.0%
Q2 2014$422,0009,4000.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q4 2017
NameSharesValueWeighting ↓
First Light Asset Management, LLC 213,887$29,608,0002.19%
Rock Springs Capital Management LP 566,500$78,421,0001.66%
FEDERATED HERMES, INC. 4,280,528$592,554,0001.21%
AtonRa Partners 17,646$2,443,0001.20%
EMERALD MUTUAL FUND ADVISERS TRUST 218,390$30,232,0001.05%
EMERALD ADVISERS, LLC 226,875$31,406,0001.04%
Atika Capital Management LLC 89,000$12,319,0000.96%
Capital Impact Advisors, LLC 25,582$3,541,0000.87%
JGP Global Gestao de Recursos Ltda. 1,586$220,0000.83%
CAPITAL INTERNATIONAL LTD /CA/ 79,742$11,039,0000.64%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders